Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
基本信息
- 批准号:6543596
- 负责人:
- 金额:$ 37.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-05-01 至 2006-06-30
- 项目状态:已结题
- 来源:
- 关键词:antithrombins atherosclerosis blood proteins carbohydrate structure clinical research cofactor embryonic stem cell enzyme activity enzyme inhibitors enzyme structure genetically modified animals hemostasis heparin human subject human tissue immunocytochemistry laboratory mouse mucopolysaccharides mutant protein protein interaction protein structure function synthetic peptide thrombin
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of this project is to elucidate the mechanism of action and physiologic function of heparin cofactor H (HCII). HCII is an inhibitor of thrombin that is present in plasma at a concentration of -1 uM. The anticoagulant activity of HCII is greatly increased by heparin or dermatan sulfate, and dermatan sulfate proteoglycans on the surface of fibroblasts and smooth muscle cells stimulate HCH. Previously, cDNA and genomic clones for human and murine HCII were isolated, recombinant HCII was expressed in E. coli, site-directed mutagenesis was performed to identify important amino acid residues that interact with thrombin and glycosaminoglycans, and the structure of a high-affinity hexasaccharide that binds HCII in porcine skin dermatan sulfate was identified. Although the function of HCII in vivo remains unknown, indirect evidence suggests that HCII activity increases during pregnancy and perhaps serves to inhibit coagulation of maternal blood in the placenta. In addition, the presence of HCII in the intima of normal human arteries and the altered composition of dermatan sulfate (with reduced HCII-stimulating activity) in atherosclerotic lesions provide circumstantial evidence of a role for HCII in atherogenesis. By means of targeted gene disruption in embryonic stem cells, a murine model of HCII deficiency has been developed. The following specific aims are proposed: (1) Determine the effects of HCII deficiency on hemostasis, atherogenesis, wound repair, and inflammation in the mouse. (2) Determine the location of endogenous HCH in human and murine tissues by immunohistochemical methods and identify binding Sites for exogenous HCII in tissue sections. (3) Characterize the oligosaccharide structures in glycosaminoglycans derived from placenta and other tissues that are required for interaction with HCII. (4) Determine the prevalence of HCII deficiency in patients with atherosclerosis. New information about the structure, mechanism of action, and function of HCII in vivo will provide a better understanding of the regulation of thrombin activity under normal and pathologic conditions.
项目描述(由申请人提供):本项目的长期目标是阐明肝素辅助因子H (HCII)的作用机制和生理功能。HCII是一种凝血酶抑制剂,存在于血浆中浓度为-1 μ m。肝素或硫酸皮聚糖可显著提高HCII的抗凝血活性,成纤维细胞和平滑肌细胞表面的硫酸皮聚糖可刺激HCH。在此之前,我们分离了人类和小鼠HCII的cDNA和基因组克隆,在大肠杆菌中表达了重组HCII,通过定点诱变鉴定了与凝血酶和糖胺聚糖相互作用的重要氨基酸残基,并鉴定了猪皮肤硫酸盐中与HCII结合的高亲和力六糖的结构。虽然HCII在体内的功能尚不清楚,但间接证据表明,HCII的活性在怀孕期间增加,可能有助于抑制胎盘中母体血液的凝固。此外,HCII在正常人动脉内膜中的存在以及动脉粥样硬化病变中皮肤硫酸酯成分的改变(刺激HCII活性降低)为HCII在动脉粥样硬化中的作用提供了间接证据。通过对胚胎干细胞进行靶向基因破坏,建立了小鼠HCII缺陷模型。提出以下具体目的:(1)确定HCII缺乏对小鼠止血、动脉粥样硬化、伤口修复和炎症的影响。(2)通过免疫组织化学方法确定内源性HCH在人和小鼠组织中的位置,并在组织切片中确定外源性HCII的结合位点。(3)表征来自胎盘和其他组织的糖胺聚糖中与HCII相互作用所需的低聚糖结构。(4)确定动脉粥样硬化患者HCII缺乏的患病率。关于HCII在体内的结构、作用机制和功能的新信息将有助于更好地理解正常和病理条件下凝血酶活性的调节。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DOUGLAS M TOLLEFSEN其他文献
DOUGLAS M TOLLEFSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DOUGLAS M TOLLEFSEN', 18)}}的其他基金
Antithrombotic Activity of Ascidian Glycosaminoglycans
海鞘糖胺聚糖的抗血栓活性
- 批准号:
6622188 - 财政年份:2002
- 资助金额:
$ 37.95万 - 项目类别:
Antithrombotic Activity of Ascidian Glycosaminoglycans
海鞘糖胺聚糖的抗血栓活性
- 批准号:
6441300 - 财政年份:2002
- 资助金额:
$ 37.95万 - 项目类别:
Antithrombotic Activity of Ascidian Glycosaminoglycans
海鞘糖胺聚糖的抗血栓活性
- 批准号:
6696337 - 财政年份:2002
- 资助金额:
$ 37.95万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
7649349 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
6763078 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
STRUCTURE AND FUNCTION OF HEPARIN COFACTOR II
肝素辅因子 II 的结构和功能
- 批准号:
2415676 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
6616222 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
STRUCTURE AND FUNCTION OF HEPARIN COFACTOR II
肝素辅因子 II 的结构和功能
- 批准号:
2234112 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
Structure and Function of Heparin Cofactor II
肝素辅因子 II 的结构和功能
- 批准号:
7143559 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
STRUCTURE AND FUNCTION OF HEPARIN COFACTOR II
肝素辅因子 II 的结构和功能
- 批准号:
6184419 - 财政年份:1996
- 资助金额:
$ 37.95万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
- 批准号:
10537602 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
- 批准号:
2880683 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
Studentship
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
- 批准号:
23K15842 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
- 批准号:
10570469 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
- 批准号:
10585070 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
- 批准号:
10619831 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS - TOPMED
动脉粥样硬化的多种族研究 - TOPMED
- 批准号:
10974007 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别: